Few IPOs Fighting the Biotech Tide
This article was originally published in Start Up
Executive Summary
The thirteen biotech companies that have listed this year are hardly the poster children for good returns. But even after various haircuts and modest step-ups (the average pre-money step up for our group here is roughly 2.5) 2005's class has continued to suffer once public trading commences.
You may also be interested in...
Biotechnology Fundraising Reflects Bigger Start-Ups, Fewer IPOs in 2005
Fundraising among private biotechs has evened out this year, with larger early rounds reflecting the renewed "think-big" strategy of some start ups, and larger late rounds a consequence of less receptive IPO markets.
Biotechnology Fundraising Reflects Bigger Start-Ups, Fewer IPOs in 2005
Fundraising among private biotechs has evened out this year, with larger early rounds reflecting the renewed "think-big" strategy of some start ups, and larger late rounds a consequence of less receptive IPO markets.
Trade Sales Trump IPOs, Even for Platforms
Europe's summertime flurry of private biotech sell-offs points to growing pragmatism among management and VCs, and still-poor valuations on the public markets. Firms which haven't already considered the trade sale opportunity should do so--even early-stage, pre-product platform groups.